La IA permite diseñar nuevas moléculas que actúan selectivamente contra células concretas

The classical drug discovery paradigm begins with a known molecular target: a protein whose modulation is expected to reverse the course of a disease. However, in many pathologies, such a target does not always exist or is not sufficiently characterized.

Now, the Structural Bioinformatics and Network Biology lab at IRB Barcelona, led by Dr. Patrick Aloy, proposes a new strategy to design molecules based not on a specific protein, but on the effect they wish to induce in cells.

TanyaY

Stats

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.